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Introduction {#sec005}
============

Enterovirus 71 (EV71) was first isolated in California, USA in 1969 \[[@pone.0224110.ref001]\]. Since then, EV71 emerged in various regions throughout the world \[[@pone.0224110.ref002]--[@pone.0224110.ref007]\]. Large-scale outbreaks with frequent central nervous system (CNS)-complicated cases and deaths were found in Bulgaria, Hungary, Malaysia, Taiwan, Vietnam, Brunei, China and Cambodia \[[@pone.0224110.ref002]--[@pone.0224110.ref008]\]. An EV71 epidemic swept Taiwan in 1998, which caused 405 severe cases and 78 deaths \[[@pone.0224110.ref008]--[@pone.0224110.ref012]\]. After the epidemic, multiple and real-time national enterovirus surveillance systems were established by the Taiwan Centers for Disease Control, including viral lab network; outpatient, inpatient, and emergency room visits for hand-foot-and-mouth-disease (HFMD) and/or herpangina (HA); and mandatory notification of enterovirus severe cases \[[@pone.0224110.ref013]--[@pone.0224110.ref016]\]. After the first EV71 epidemic in 1998, EV71 cases occurred again in 2000--2001, 2005, 2008, and 2012 based on the surveillance data \[[@pone.0224110.ref015]--[@pone.0224110.ref017]\]. There seems to be a nationwide EV71 epidemic every 3 to 5 years. In addition to Taiwan, EV71 has emerged as a major concern among children in the Asia-Pacific region during recent 20 years \[[@pone.0224110.ref004],[@pone.0224110.ref006],[@pone.0224110.ref007]\].

After several epidemics, there is an urgent need to understand the current EV71 serostatus of high-risk groups and the high transmission population to predict future epidemics and to establish future EV71 vaccine policy \[[@pone.0224110.ref018]\]. In addition, we can compare the seroepidemiology in different years to determine the temporal change in the EV71 endemics in Taiwan. We thus performed this seroepidemiology study.

Methods {#sec006}
=======

Study subjects {#sec007}
--------------

The Institutional Review Board of the National Taiwan University Hospital approved this study. After written informed consent was obtained from parents or guardians of children, we enrolled preschool children, 6--11-year-old primary school students and 12--15-year-old high school students in the northern (Taipei City), eastern (Hualien County), western (Yunlin County) and southern (Kaohsiung City) regions of Taiwan between May and November 2017. Community-dwelling 16-50-year-old healthy people were also enrolled in the four different regions of Taiwan after their own written informed consent was obtained. Participants received a questionnaire, and a blood sample was collected and submitted for measuring the EV71 neutralization antibody.

Data collection for the serosurvey {#sec008}
----------------------------------

The questionnaire solicited demographic data, residential area, number of children and adults in a family, vaccination history, past history of HFMD and/or HA, intrafamilial or outside contact with HFMD and/or HA cases, family members with HFMD and/or HA, classmates or neighbors with HFMD and/or HA, sources of drinking water, employment of a babysitter, enrollment in a kindergarten or childcare center, and breastfeeding during infancy. No EV71 vaccine is licensed in Taiwan up to now. Contact with HFMD and/or HA cases was defined as kissing, hugging, shaking hands, sharing food, or playing with children who had HFMD and/or HA. All interviewers were trained, and contact history information was collected from several family members to minimize recall bias. The questionnaires for preschool children, students and adults are listed in the supplementary files ([S1](#pone.0224110.s001){ref-type="supplementary-material"}, [S2](#pone.0224110.s002){ref-type="supplementary-material"} and [S3](#pone.0224110.s003){ref-type="supplementary-material"} Files).

Laboratory methods for the EV71 neutralizing antibody {#sec009}
-----------------------------------------------------

The serum neutralizing antibody response is the major indicator of EV71 protective immunity. The neutralizing antibody test of EV71 followed the standard protocol of a neutralization test. Serum samples were heat-treated for 30 minutes at 56°C, serially diluted and mixed with 100 50% tissue culture-infective doses (TCID50) of the EV71 TW/2272/98 strain (GenBank accession number AF119795), and incubated for 2 hours at 37°C. Thereafter, rhabdomyosarcoma cells were added into each reaction well and incubated at 37°C in 5% CO~2~ incubator. Each plate included a cell control, serum control, and virus back-titration. The cytopathic effect was monitored from 5 to 6 days after incubation, and the serotiter was determined when the cytopathic effect was observed in one TCID50 of the virus back-titration. Seropositivity was defined as a serotiter ≥8. For details, please see <http://dx.doi.org/10.17504/protocols.io.7pwhmpe>.

Comparison of EV71 serostatus among 1997, 1999, 2007 and 2017 {#sec010}
-------------------------------------------------------------

We previously performed EV71 seroepidemiology studies in 1997, 1999, and 2007, which were conducted by Dr. Luan-Yin Chang and Dr. Tzou-Yien Lin \[[@pone.0224110.ref019]\]. The method for neutralization antibody measurement was the same. We thus compared the age-specific seropositive rates among different years.

Statistical analyses {#sec011}
--------------------

We analyzed the data with the SAS statistical software (version, SAS Institute, Cary, North Carolina). We used Student's *t*-test for continuous data and chi-squared tests for categorical data. A p value \<0.05 indicated a statistical significance.

Results {#sec012}
=======

Demography and EV71 serostatus in 2017 {#sec013}
--------------------------------------

We conducted nationwide recruitment from urban and rural regions, as [Table 1](#pone.0224110.t001){ref-type="table"} shows. Taipei City and Kaohsiung City, two metropolitan areas, are located in the northern and southern regions of Taiwan, whereas Hualien County and Yunlin County, two rural areas, are located in the eastern and western regions of Taiwan.

10.1371/journal.pone.0224110.t001

###### Age-specific EV71 seropositive rates in four different regions of Taiwan in 2017.

![](pone.0224110.t001){#pone.0224110.t001g}

  ------------------------------------------------------------------------------------------------
  Age in years   Overall         Taipei\       Kaohsiung\    Yunlin\       Hualien\      p value
                                 (N)           (S)           (W)           (E)           
  -------------- --------------- ------------- ------------- ------------- ------------- ---------
  **\<1**        10% (8/82)      10% (3/29)    5% (1/21)     16% (4/25)    0% (0/7)      0.48

  **1**          4% (6/153)      10% (3/31)    2% (1/45)     0% (0/32)     4% (2/45)     0.22

  **2**          8% (7/83)       14% (4/28)    0% (0/9)      4% (1/23)     9% (2/23)     0.46

  **3--5**       8% (13/156)     4% (3/70)     0% (0/26)     14% (4/29)    19% (6/31)    0.02

  **6--11**      31% (38/122)    20% (6/30)    21% (7/34)    37% (10/27)   48% (15/31)   0.04

  **12--15**     45% (54/121)    26% (8/31)    54% (15/28)   45% (14/31)   55% (17/31)   0.08

  **16--50**     75% (152/203)   73% (37/51)   63% (32/51)   84% (42/50)   80% (41/50)   0.07
  ------------------------------------------------------------------------------------------------

The p value was measured by chi-squared test. N denotes the northern region, W is the western region, S is the southern region, and E is the eastern region. Taipei City and Kaohsiung City are metropolitan areas, whereas Hualien County and Yunlin County are rural areas.

In total, 920 subjects were enrolled with a male-to-female ratio of 1.03. Direct standardization method was applied to calculate age-region standardized seroprevalence for male and female, using the population of Taipei City, Hualien County, Yunlin County and Kaohsiung City in 2017 as the standard population. Overall, females had significantly greater seropositive rates than males, as [Fig 1](#pone.0224110.g001){ref-type="fig"} shows (p = 0.01). The EV71 seropositive rate was 10% (8/82) in infants, 4% (6/153) in 1-year-old children, 8% (7/83) in 2-year-old children, 8% (13/156) in 3--5-year-old children, 31% (38/122) in 6--11-year-old primary school students, 45% (54/121) in 12--15-year-old high school students, 80% (97/122) in 16-50-year-old women and 68% (55/81) in 16-50-year-old men in 2017.

![Age-specific EV71 serostatus between males and females in 2017.\
Overall, females had significantly greater seropositive rates than males (p = 0.01).](pone.0224110.g001){#pone.0224110.g001}

There was significant difference of seropositive rates among preschool and primary student children between the rural areas and metropolitan areas, as [Table 1](#pone.0224110.t001){ref-type="table"} shows. The seropositive rates of 3--5-year-old kindergarteners and 6--11-year-old primary school children were significantly greater in rural areas (Hualien County and Yunlin County) than in metropolitan areas (Taipei City and Kaohsiung City). Among the four regions, there were no significant differences in the age and gender of the enrolled people, but the family size was larger (4.4±1.8 vs. 3.9±1.7, p\<0.001) and the rate of drinking spring or well water was significantly greater (18% vs. 9%, p\<0.05) in rural areas than in metropolitan areas.

Risk factors associated with EV71 seropositivity {#sec014}
------------------------------------------------

[Table 2](#pone.0224110.t002){ref-type="table"} shows risk factors associated with EV71 seropositivity in preschool children aged less than 6 years old and significant risk factors were female gender, having siblings, more siblings, and contact with HFMD and/or HA. Residential areas, breast feeding, vaccination history, and source of drinking water did not affect the EV71 seropositivity in preschool children.

10.1371/journal.pone.0224110.t002

###### Risk factors associated with EV71 seropositivity in preschool children in 2017.

![](pone.0224110.t002){#pone.0224110.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------
  Factor\                                                                  Seropositive\   Seronegative\   OR, 95% CI            p value
                                                                           (N = 34)        (N = 440)                             
  ---------------------------------------------------------- ------------- --------------- --------------- --------------------- ---------
  **Sex**                                                    Male          13 (38.2%)      245 (55.7%)     Ref.                  

                                                             Female        21 (61.8%)      195 (44.3%)     2.03, (1.00, 4.26)    0.05

  **Age (years)**                                            Mean**±**SD   2.8**±**1.8     2.5**±**1.6                           0.45

  **Residential area**                                       City          23 (67.6%)      287 (65.2%)     Ref.                  

                                                             Village       9 (26.5%)       113 (25.7%)     0.45, (0.45, 2.21)    0.99

                                                             Suburban      2 (5.9%)        35 (8.0%)       0.71, (0.16, 3.15)    0.66

                                                             Industrial    0 (0%)          5 (1.1%)        NA                    

  **Household size**                                         Mean**±**SD   4.1**±**1.7     4.3**±**1.8                           0.53

  **Sibling**                                                No            6 (17.7%)       167 (38.0%)     Ref.                  

                                                             Yes           28 (82.3%)      273 (62.0%)     2.85, (1.16, 7.04)    0.02

                                                             Mean**±**SD   1.2**±**1.0     0.8**±**0.8                           0.005

  **History of chronic illness**                             No            29 (85.3%)      404 (91.8%)     Ref.                  

                                                             Yes           5 (14.7%)       36 (8.2%)       1.93, (0.71, 5.30)    0.19

  **Ever breastfed**                                         No            1 (2.9%)        31 (7.1%)       Ref.                  

                                                             Yes           33 (97.1%)      409 (92.9%)     2.50, (0.33, 18.89)   0.36

  **Attendance of kindergartens or daycare center**          No            9 (26.5%)       163 (37.1%)     Ref.                  

                                                             Yes           25 (73.5%)      277 (62.9%)     1.64, (0.75, 3.59)    0.22

  **Main source of drinking water**                          Tap water     19 (55.9%)      260 (59.1%)     Ref.                  

                                                             Well water    0 (0%)          2 (0.5%)        NA                    

                                                             Spring        4 (11.8%)       51 (11.5%)      1.07, (0.35, 3.29)    0.90

                                                             Others        11 (32.3%)      127 (28.9%)     1.19, (0.55, 2.57)    0.67

  **History of HFMD**                                        No            22 (64.7%)      334 (75.9%)     Ref.                  

                                                             Yes           11 (32.4%)      99 (22.5%)      1.69, (0.79, 3.60)    0.18

                                                             Unknown       1 (2.9%)        7 (1.6%)                              

  **History of herpangina**                                  No            26 (76.5%)      316 (71.8%)     Ref.                  

                                                             Yes           8 (23.5%)       110 (25.0%)     0.88, (0.39, 2.01)    0.77

                                                             Unknown       0 (0.0%)        14 (3.2%)                             

  **Family member with history of HFMD and/or herpangina**   No            20 (58.8%)      288 (65.5%)     Ref.                  

                                                             Yes           13 (38.2%)      134 (30.4%)     1.40, (0.68, 2.89)    0.37

                                                             Unknown       1 (2.9%)        18 (4.1%)                             

  **Classmates with history of HFMD and/or herpangina**      No            1 (2.9%)        38 (8.6%)       Ref.                  

                                                             Yes           19 (55.9%)      134 (30.5%)     5.39, (0.70, 41.56)   0.11

                                                             Unknown       14 (41.2%)      268 (60.9%)                           

  **Contact with history of HFMD or herpangina**             No            7 (20.6%)       173 (39.3%)     Ref.                  

                                                             Yes           18 (52.9%)      144 (32.7%)     3.09, (1.26, 7.60)    0.01

                                                             Unknown       9 (26.5%)       123 (28.0%)                           
  ----------------------------------------------------------------------------------------------------------------------------------------

The p values were measured by Student's t-test or chi-squared test. SD denotes standard deviation; HFMD, hand, foot and mouth disease; OR, odds ratio; CI, confidence interval; NA, not available.

For the 6 to 15 year-old children, no significant risk factors were found except older age. For 16-50-year-old people, the significant risk factor associated with EV71 seropositivity was having children in addition to older age: 61% of seropositive 16-50-year-old people had children in their families but only 27% of seronegative 16-50-year-old people had children in their families (p\<0.001).

Comparison of EV71 serostatus among 1997, 1999, 2007 and 2017 {#sec015}
-------------------------------------------------------------

[Fig 2](#pone.0224110.g002){ref-type="fig"} shows age-specific seropositive rates among 1997, 1999, 2007 and 2017. Infants might have maternal antibodies, so they did not have significantly different seropositive rates among different years (p = 0.62). Compared with EV71 seropositive rates in 1997 and 1999, the rates in 2--11-year-old children were significantly lower in 2007 and 2017 as [Fig 2](#pone.0224110.g002){ref-type="fig"} shows (p\<0.001). The seropositive rates of the 6- to 19-year-olds in 2017 were significantly lower than those rates in 1997, 1999 and 2007 (p\<0.001). There were no significant differences in 20- to 29-year-old adults among the four different periods (p = 0.36). Overall, the seropositive rates in 2017 were the lowest among the four periods.

![Age-specific EV71 serostatus in Taiwan in 1997, 1999, 2007, and 2017.\
Infants did not have significantly different seropositive rates among different years (p = 0.62). The rates in 2--11-year-old children were significantly lower in 2007 and 2017 than those rates in 1997 and 1999 (p\<0.001). The seropositive rate of the 6- to 19-year-olds in 2017 was significantly lower than those rates in 1997, 1999 and 2007 (p\<0.001). The seropositive rates of 20- to 29-year-old adults were not significantly different among the 4 different years.](pone.0224110.g002){#pone.0224110.g002}

Discussion {#sec016}
==========

This EV71 seroepidemiology study in 2017 shows that seropositive rates in children were significantly lower in comparison with those rates in 1999 \[[@pone.0224110.ref019],[@pone.0224110.ref020]\], one year after the first epidemic occurred in Taiwan in 1998. The EV71 seropositive rates in 2017 were very low, at 4% to 10%, in the very-high-risk group (\<6-year-old preschool children) and not high, at 31%, in primary school students. The risk factors associated with seropositivity in preschool children included female gender, having siblings, more siblings, and contact with HFMD and/or HA whereas the only risk factor associated with seropositivity in adults was having children in the family in addition to older age.

The lower seropositive rates in young children observed in 2007 and 2017 correlate well with the fact that there were no major EV71 outbreaks during the last 10 years. Factors underlying the decreasing seropositivity may include lower birth rates and strict implementation of preventive measures during this time period \[[@pone.0224110.ref021]\]. The low birth rate and having only one child in most families in Taiwan make children get EV71 infection at an older age in comparison with the previous periods of the late 1990s or early 2000s. In our previous study conducted in 2001--2002, we found a very high EV71 household transmission rate of 84% among siblings if there were any siblings infected with EV71 in the household \[[@pone.0224110.ref022]\]. Taiwan has the sixth-lowest birth rate in the world, according to the most recent data released by the Central Intelligence Agent World Factbook \[[@pone.0224110.ref023]\], and the fertility rate in Taiwan was only 1.13 children per woman in 2017 and 1.218 children per woman in 2018, which was the third lowest in the world \[[@pone.0224110.ref023]\]. Because of having only one child in most families in recent years, there is no elder sibling(s) to spread viruses, including EV71, into the other family members; thus, most children acquire viral infection when they go to school or kindergarten. Therefore, the age of getting EV71 becomes older than in previous periods. In addition, EV71 infection at different ages has different symptomatic ratios and severity \[[@pone.0224110.ref019]\]. The symptomatic ratios are much lower \[[@pone.0224110.ref019]\], and the severity is milder when children get an EV71 infection at older ages \[[@pone.0224110.ref013], [@pone.0224110.ref024]\].

After the nationwide EV71 epidemic that occurred in Taiwan in 1998, multiple and real-time national enterovirus surveillance systems have been established by the Taiwan Centers for Disease Control since 2000 and include viral lab network; outpatient, inpatient, and emergency room visits for HFMD and/or HA from National Health Insurance claim data; and mandatory notification of enterovirus severe cases \[[@pone.0224110.ref013]--[@pone.0224110.ref016], [@pone.0224110.ref021]\]. The real-time EV surveillance makes early detection of EV71 possible, and strict implementation of preventive measures during EV71 circulation periods are applied, so these preventative measures may limit the spread of EV71 \[[@pone.0224110.ref021]\]. For example, to reduce the risk of enterovirus clustering, class suspension has been executed for the pre-school education and care institutions. Strengthened implementation of infection control measures is applied in hospitals and postpartum nursing care centers to reduce the risk of enterovirus clusters. For medical care of severe enterovirus cases, Taiwan Centers for Disease Control have constructed a medical service network for recent 2 decades and workshops are held on the clinical treatment of critical enterovirus complications to enhance doctors' skills every year. There has been a marked decrease in severe and fatal EV71 cases after 2012 \[[@pone.0224110.ref017]\], and the results of this seroepidemiology study also endorse the impact of a well-established real-time enterovirus surveillance system and all the preventive measures to limit the spread of EV71 in Taiwan. Other speculations may include viral evolution, as evidenced by EV71-like gene elements appearing in other cocirculating EV-A viruses by intensive recombination \[[@pone.0224110.ref025]\]. The virulence of EV71 could thus be modified. Overall, the viral (recombination and mutation), host (low birth rate) and environmental (increased surveillance) factors might change transmission dynamics of EV71. However, with the accumulation of a susceptible high-risk group during the past 20 years, new epidemics could occur in the years to come. Careful monitoring and preventive measures are still necessary.

Risk factors associated with EV71 seropositivity were female gender, having siblings, more siblings, classmates with HFMD and/or HA and contact with HFMD and/or HA in high-risk groups. The seropositive rate in females is significantly greater than in males. However, the male-to-female ratio of symptomatic and/or severe enterovirus infections shifted toward males and was approximately 1.5 \[[@pone.0224110.ref010],[@pone.0224110.ref013],[@pone.0224110.ref024]\]. The role of gender on the susceptibility to EV71 and the severity of EV71 infections remains unclear and needs further investigation.

Among different regions in Taiwan, 3- to 5-year-old children and primary school students in rural areas had greater seropositive rates. In our previous seroepidemiology conducted in 1999, living in rural areas was also a significant risk factor for EV71 infection \[[@pone.0224110.ref019]\]. The possible reasons may be poorer hygiene behaviors and larger family size, resulting in more possible contacts and transmissions of EV71 in rural areas. The socioeconomic and educational gaps between urban and rural areas might affect the parents' and/or caregivers' hygiene behavior, which would in turn have some impact on the infection incidence and/or severity. For example, caregivers in the critical group (encephalitis with or without cardiopulmonary failure) of EV71 infection had a significantly lower rate in terms of cleaning the faucet after washing their hands, as our previous study reported \[[@pone.0224110.ref024]\].

Young children in Taiwan have very low EV71 seropositive rates now and therefore harbor a high risk of developing an EV71 infection. Our earlier studies also showed that young children are at especially high risk of developing severe disease after EV71 infections \[[@pone.0224110.ref024]\]. Future EV71 vaccine policy should be targeted to young children, who will be the first priority to receive the EV71 vaccine in Taiwan.

For 16-50-year-old people, the significant risk factor associated with EV71 seropositivity was having children in addition to older age. Bidirectional transmission of EV71 between children and parents or other household adults does occur, parents or other household adults might transmit EV71 to their children and vice versa. For example, a Japanese mother developed encephalitis caused by intrafamilial transmission of EV71 from her 1-year-old son and it also elucidated the risk for EV71 encephalitis even in adults \[[@pone.0224110.ref026]\]. Therefore, parents and other household adults have to be cautious and take preventive measures once their children have such infection.

We further compared EV71 serostatus among different countries in [Table 3](#pone.0224110.t003){ref-type="table"}. Among different countries, the EV71 seropositive rates varied greatly. The seropositive rates of children in China, Thailand and Cambodia were very high, ranging from 35 to 98% \[[@pone.0224110.ref027]--[@pone.0224110.ref031]\]. The rates (15 to 37%) of children in Singapore in 2008--2010 were comparable to those in Taiwan in 2007 and 2017 \[[@pone.0224110.ref028]\]. The rates in Russia varied in different regions: the rates were lower (5 to 19%) in urban areas, such as Moscow and Rostov, than those (20 to 83%) in rural areas, such as Tyva \[[@pone.0224110.ref029]\]. Severe EV71 cases occurred more frequently in countries, such as China and Cambodia which had greater seropositive rates \[[@pone.0224110.ref007], [@pone.0224110.ref023], [@pone.0224110.ref031]--[@pone.0224110.ref033]\] and it indicates greater disease burden in these countries. EV71 outbreak occurred in Cambodia in 2012, it characterized by severe encephalitis with cardiovascular collapse and pulmonary edema seized international headlines and resulted in the death of at least 54 children \[[@pone.0224110.ref031]\], and more than 2 thousands of laboratory-confirmed EV71 cases died in China from 2008 to 2015 \[[@pone.0224110.ref007]\].

10.1371/journal.pone.0224110.t003

###### Comparison of the age-specific EV71 serostatus among different countries.

![](pone.0224110.t003){#pone.0224110.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
           Country and Year                                                                                                                                                                                                                                                                          
  -------- ------------------ ----------- ----------- ---------- --------------------------------------------- -------------------------------------------- ----------------------------------------------- -------------------------------------------- ------------------------------------------- -----------------------------------------------
  Age      1997               1999        2007        2017       2014--2015                                    2008--2010                                   2007--2008                                      2009--2012                                   2000--2005                                  2006--2011

  \<1      9%\                10%\        3%\         10%\       35% [^a^](#t003fn004){ref-type="table-fn"}\   NA                                           NA                                              43%[^d^](#t003fn007){ref-type="table-fn"}\   NA                                          NA
           (5/56)             (60/589)    (1/32)      (8/82)     (6/17)                                                                                                                                     (17/40)                                                                                  

  1        4%\                16%\        1%\         4%\                                                                                                   NA                                              NA                                                                                       
           (2/50)             (65/407)    (1/89)      6/153)                                                                                                                                                                                                                                         

  2        22%\               24%\        8%\         8%\        43%\                                          15%[^b^](#t003fn005){ref-type="table-fn"}\   5--20%[^c^](#t003fn006){ref-type="table-fn"}\   52%                                          93%                                         
           (4/19)             (86/365)    (9/118)     (7/83)     (26/60)                                       (16/104))                                    (3/67-11/54)                                                                                                                             

  3--5     36%\               42%\        14%\        8%\        71%\                                                                                       19--83%\                                        48%\                                         52--76%                                     93--97%
           (9/25)             (309/730)   (42/311)    (13/156)   (85/120)                                                                                   (16/82-70/84)                                   (14/29)                                                                                  

  6--11    63%\               61%\        47%\        31%\       NA                                            26%\                                         NA                                              88%\                                         50%[^e^](#t003fn008){ref-type="table-fn"}   88--98%
           (18/29)            (461/761)   (338/717)   (38/122)                                                 (77/294)                                                                                     (30/34)                                                                                  

  12--19   66%\               65%\        65%\        46%\       NA                                            37%\                                         NA                                              80%\                                         NA                                          86--98%[^f^](#t003fn009){ref-type="table-fn"}
           (51/78)            (419/648)   (459/705)   (60/134)                                                 (112/302)                                                                                    (24/30)                                                                                  

  20--29   57%\               64%\        68%\        65%\       NA                                            NA                                           NA                                              77%\                                         NA                                          NA
           (29/51             (229/358)   (339/500)   (49/75)                                                                                                                                               (17/22)                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The cutoff for EV71 seropositivity was ≥1:8 \[[@pone.0224110.ref019], [@pone.0224110.ref027]--[@pone.0224110.ref030]\], except in the Cambodia study, which used a titer of ≥1:16 as the cutoff \[[@pone.0224110.ref031]\].

NA: not available.

Numbers in parenthesis are case number with EV71 seropositivity/case number tested but those numbers are not available in Cambodia.

^a^The rate for children younger than 2 years \[[@pone.0224110.ref027]\].

^b^The rate for 1--6 year-old children \[[@pone.0224110.ref028]\].

^c^The rate for 1--2 year-old children \[[@pone.0224110.ref029]\].

^d^The rate for 6 month-old to 2 year-old children \[[@pone.0224110.ref030]\].

^e^The rate for 6 year-old children \[[@pone.0224110.ref031]\].

^f^The rate for 12 to 15 year-old adolescents \[[@pone.0224110.ref031]\].

There are some limitations in this study. First, the test population (sampling methods, geographical and demographical characteristics) were not the same with those previous studies of 1997, 1999 and 2007 in Taiwan although the laboratory method was the same. Second, the sample size of young children was small and the power may be limited, so larger sample size and multiple test correction may be needed in the future to verify our findings. Third, the EV71 viral strains used for neutralizing antibody, cut-off criteriae for seropositivity and the age groups are different among different countries. Although the seroprevalence rates were not so comparable, we tried our best to clarify the difference and did some important comparisons.

Conclusions {#sec017}
===========

The EV71 seropositive rates were very low, at 4% to 10%, in the high-risk group (\<6-year-old preschool children) and not high, at 31%, in primary school students. Female gender, having siblings, more siblings and contact with HA or HFMD were factors associated with EV71 seropositivity in children younger than 6 years of age while having children in the family and older age were factors associated with EV71 seropositivity in 16-50-year-old people. Young children will be the group with the greatest priority to receive the EV71 vaccine.

Supporting information {#sec018}
======================

###### Questionnaire for preschool children with Chinese-English parallel texts.

(PDF)

###### 

Click here for additional data file.

###### Questionnaire for students with Chinese-English parallel texts.

(PDF)

###### 

Click here for additional data file.

###### Questionnaire for adults with Chinese-English parallel texts.

(PDF)

###### 

Click here for additional data file.
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Dong-Yan Jin

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62> /PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.  We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (<http://learn.aje.com/plos/>) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website ([www.editage.com](http://www.editage.com)) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscriptA copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a \*supporting information\* file)A clean copy of the edited manuscript (uploaded as the new \*manuscript\* file

3\. We noticed you have some minor occurrence of overlapping text with the following previous publication, which needs to be addressed:

\- <https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-019-0552-7>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

Additionally, please address the following:

\- whether a prior sample size calculation was carried out for this study

\- the rationale for the lack of multiple test correction in your statistical analysis

\- ensure you include details concerning the pretesting of your questionnaire included in this study and also a copy of it

Additional Editor Comments:

Please respond to reviewers\' comments and provide the requested information if available.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript "Enterovirus 71 Seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007" provided an updated serostatus of EV71 in different region of Taiwan. This is a timely study as the threat of enterovirus infection continuously posing significant concern worldwide.

Below are my comments for improvement.

1\) Is there any patient data co-relating with the seropositive specimen? For example, successful rate of detecting viral RNAs/antigens in specimens of seropositive patients; the history of seropositive patients with enterovirus-related syndromes.

2\) The authors suggested that female gender could be a risk factor of EV71 seropositivity. The comparison appears to be based on the absolute number of seropositivity in between male and female. The comparison may be subjected to the biases due to disproportion of male:female ratio within the community. The authors may need to consider this point and perform normalization accordingly.

3\) The number of tested specimen (n) needs to be indicated in table 3.

4\) The authors suggested the lower EV71 seropositivity detected in specimen of 2007 and 2017 could be due to the absence of disease outbreak. Does the high seropositivity detected in other countries, for example, Cambodia (Table 3), correlate to an EV71 outbreak?

5\) Figure 2 showed similar but delayed trend of EV71 seropositivity between specimens obtained from 1997 and 1999 to 2007 and 2017. For example, an age 1 EV71 seropositive specimen detected in 1999 will become an age 8 EV71 seropositive specimen detected in 2007. In other words, the delay could be an indication of effective infectious disease control. The authors should discuss what infectious disease control policy may have been implemented during this period of time. When comparing with data from other countries, which ways do Taiwan do better or worse?

Reviewer \#2: Comments to the Author

The manuscript aims to explore the EV71 serostatus in Taiwan. The authors made efforts to test the EV71 neutralizing antibody with serum samples and compared EV71 serostatus among 1997, 1999, 2007 and 2017. They illustrated that the EV71 seropositive rates in children were significantly lower in 2017, compared with the rates in 1997, 1999 and 2008. These results prompt the necessity of continuous surveillance for the prevention and control of the disease infected with EV71. The main limitations of the manuscript are listed below.

1\. Did the questionnaire include the subjects\' vaccination history?

2\. As the authors indicated that the male-to-femal ratio of symptomatic and/or severe enterovirus infections shifted toward males in the discussion section. While the female gender was the risk factors associated with EV71 seropositivity in this study, and this conclusion was based the analysis of in preschool children in 2017. The risk factors could be analyzed including other ages.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Man Lung YEUNG

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewers\' comments:

Comments to the Author

Reviewer \#1: The manuscript "Enterovirus 71 Seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007" provided an updated serostatus of EV71 in different region of Taiwan. This is a timely study as the threat of enterovirus infection continuously posing significant concern worldwide.

Response: thank you very much for your comment and appreciation.

Below are my comments for improvement.

1\) Is there any patient data co-relating with the seropositive specimen? For example, successful rate of detecting viral RNAs/antigens in specimens of seropositive patients; the history of seropositive patients with enterovirus-related syndromes.

Response: we did not have any data of detecting viral RNAs/antigens in specimens of seropositive patients, but we did have data on enterovirus-related ( HFMD or herpangina) history of seropositive children in Table 2. For example, 34% of seropositive preschool children had history of HFMD and 24% had history of herpangina (Table 2).

2\) The authors suggested that female gender could be a risk factor of EV71 seropositivity. The comparison appears to be based on the absolute number of seropositivity in between male and female. The comparison may be subjected to the biases due to disproportion of male:female ratio within the community. The authors may need to consider this point and perform normalization accordingly.

Response: we agree with this comment, so normalization was done for Figure 1 accordingly to minimize any disproportion of male:female ratio within the community.

3\) The number of tested specimen (n) needs to be indicated in table 3.

Response: Thank you very much for your suggestion and we added the numbers of seropositive and tested specimen in Table 3. However, only those numbers are not available in Cambodia and we can not add them.

4\) The authors suggested the lower EV71 seropositivity detected in specimen of 2007 and 2017 could be due to the absence of disease outbreak. Does the high seropositivity detected in other countries, for example, Cambodia (Table 3), correlate to an EV71 outbreak?

Response: We agree with your comment that the high seropositivity detected in other countries correlate to an EV71 outbreak. We mentioned it in the Discussion: Severe EV71 cases occurred more frequently in countries, such as China and Cambodia which had greater seropositive rates \[7, 23, 31-33\] and it indicates greater disease burden in these countries. EV71 outbreak occurred in Cambodia in 2012, it characterized by severe encephalitis with cardiovascular collapse and pulmonary edema seized international headlines and resulted in the death of at least 54 children \[31\], and more than 2 thousands of laboratory-confirmed EV71 cases died in China from 2008 to 2015 \[7\].

5\) Figure 2 showed similar but delayed trend of EV71 seropositivity between specimens obtained from 1997 and 1999 to 2007 and 2017. For example, an age 1 EV71 seropositive specimen detected in 1999 will become an age 8 EV71 seropositive specimen detected in 2007. In other words, the delay could be an indication of effective infectious disease control. The authors should discuss what infectious disease control policy may have been implemented during this period of time. When comparing with data from other countries, which ways do Taiwan do better or worse?

Response: Thank you very much for your detailed review and suggestion. We described more infectious disease control policy in the Discussion to share our experience, which may be helpful to other countries.

Reviewer \#2: Comments to the Author

The manuscript aims to explore the EV71 serostatus in Taiwan. The authors made efforts to test the EV71 neutralizing antibody with serum samples and compared EV71 serostatus among 1997, 1999, 2007 and 2017. They illustrated that the EV71 seropositive rates in children were significantly lower in 2017, compared with the rates in 1997, 1999 and 2008. These results prompt the necessity of continuous surveillance for the prevention and control of the disease infected with EV71. The main limitations of the manuscript are listed below.

1\. Did the questionnaire include the subjects\' vaccination history?

Response: The questionnaire include the subjects\' vaccination history. We deposited the questionnaires as supplementary files with Chinese-English parallel texts. We did not show it in the original manuscript since EV71 vaccine is not commercially available now in Taiwan and the current vaccination did not affect EV71 serostatus. We added it in the revised manuscript since you and the readers may be curious about it.

2\. As the authors indicated that the male-to-female ratio of symptomatic and/or severe enterovirus infections shifted toward males in the discussion section. While the female gender was the risk factors associated with EV71 seropositivity in this study, and this conclusion was based the analysis of in preschool children in 2017. The risk factors could be analyzed including other ages.

Response: Thank you very much for your suggestion. We analyzed the risk factors in the other age groups, which are shown in the text: For the 6 to 15 year-old children, no significant risk factors were found except older age. For 16-50-year-old people, the significant risk factor associated with EV71 seropositivity was having children in addition to older age: 61% of seropositive 16-50-year-old people had children in their families but only 27% of seronegative 16-50-year-old people had children in their families (p\<0.001). Therefore, we did not find gender difference in the other age groups.
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Dear Dr. Chang,

Thank you for submitting your revised manuscript. I have read it through carefully together with your response to reviewers\' comments. I am fully satisfied with the modifications you made.

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Dong-Yan Jin

Academic Editor

PLOS ONE
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Enterovirus 71 Seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007

Dear Dr. Chang:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Dong-Yan Jin

Academic Editor

PLOS ONE
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